*Table A (Supplemental Digital Content): Hemodynamic target parameters and protocol for infusions and erythrocyte transfusion.*

|  |
| --- |
| **Hemodynamic target parameters during anesthesia**ASA 1 and 2 patients without cardiac diseases or cerebral insufficiency: Stroke Volume Variation <12% *and/or* Cardiac Index > 2.5 L/min/m2 *and/or*  Mean arterial pressure >60mmHgASA 3 and 4 patients or patients with cardiac diseases and/or cerebral insufficiency: Stroke Volume Variation <12% *and/or* Cardiac Index > 2.5 L/min/m2 *and/or*  Mean arterial pressure >70mmHgTo reach the desired parameter: 1. Start with infusion protocol (see below)
2. If not successful within 15 minutes:
3. Start with norepinephrine as first choice vasopressor
 |
| **Infusion protocol** Replacement of urinary output with balanced crystalloid solution in the relationship 1:1. Additionally up to 500 ml crystalloid solution for perspiratio insensibilis.Replacement of blood loss dependent on treatment assignment, either with albumin 5% or balanced hydroxyethyl starch 6% in the relationship 1:1 up to a transfusion trigger point or a maximum of 30ml/kg/d.Additionally up to 1500 ml colloid solution for the protein loss into the third compartment. |
| **Guidelines for erythrocyte transfusion**[**1**](#_ENREF_1)

|  |  |  |  |
| --- | --- | --- | --- |
| Hemoglobin  | Risk factors | Transfusion | Evidence level |
| < 6 g/dl | - | YES | 1 C+ |
| > 6-8 g/dl | Adequately compensation,No risk factors | NO | 1 C+ |
|  | Limited compensation or Risk factors (cardiac diseases, cerebrovascular insufficiency) | YES | 1 C+ |
|  | Signs for anemic hypoxia(Tachycardia, hypotension, lactacidosis,ECG change) | YES | 1 C+ |
| 8-10 g/dl | Signs for anemic hypoxia(Tachycardia, hypotension, lactacidosis,ECG change) | YES | 2 C |
| > 10 g/dl | - | NO | 1 A |

ASA= American Society of Anesthesiologists; ECG=electrocardiogramm. |

1. German Medical Association: Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: 1. RBC Concentrates. Transfus Med Hemother 2009; 36: 362-370